Advertisement
Advertisement
Bluehep

Bluehep Drug Interactions

heparin

Manufacturer:

Brawn Labs

Distributor:

AGB Pharma

Marketer:

Ambica
Full Prescribing Info
Drug Interactions
Oral anticoagulants (i.e., warfarin) can contribute to a small extent to an increase in APTT. Heparin can contribute to an increase in PT. While these two drugs are given together, the fact that each may contribute to an increase in PT and APTT should be taken into account. Heparin is often started with or several hours after thrombolytic therapy. Close patient monitoring for clinical signs of bleeding is indicated. The APTT should also be monitored closely. Salicylates, other nonsteroidal anti-inflammatory agents, dextran, dipyridamole, clopidogrel, ticlopidine and GPIIb-IIIa antagonists interfere with platelet aggregation which increases the risk of bleeding. They should be used cautiously with monitoring for signs of hemorrhage. In addition, in some situations, when heparin is used in conjunction with GPIIb-IIIa antagonists, the dose of heparin may need to be modified.
Ethacrynic Acid: Intravenously administered ethacrynic acid can cause GI bleeding. However, a significantly higher incidence of GI bleeding has been attributed to the concurrent use of intravenous ethacrynic acid and heparin. Furosemide may be a safer alternative when diuretic therapy is indicated in the patient receiving heparin.
Acetylsalicylic Acid: In a review article of heparin therapy, it was advocated that concurrent acetylsalicylic acid administration be "scrupulously avoided". While documentation to support this interaction is incomplete, it would be prudent to avoid concurrent therapy. Acetylsalicylic acid impairs the platelet release reaction and this platelet function defect combined with the anticoagulant effect of heparin may produce a hemorrhagic tendency.
Dextran: Limited data suggest that dextran and heparin may act synergistically when administered concurrently. Although the data are inadequate to document the clinical significance of this interaction, baseline laboratory measurements of anticoagulant activity should be obtained upon initiation of concurrent therapy as well as at frequent intervals during such therapy.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement